ELTROMBOPAG (eltrombopag) by Dr. Reddy's Laboratories is tpo-receptor agonist that interacts with the transmembrane domain of the human tpo-receptor (also known as cmpl) and initiates signaling cascades that induce proliferation and differentiation of megakaryocytes leading to increased platelet production. Approved for thrombocytopenia in adult, older with persistent, chronic immune thrombocytopenia (itp) and 11 more indications.
Drug data last refreshed 1mo ago
TPO-receptor agonist that interacts with the transmembrane domain of the human TPO-receptor (also known as cMpl) and initiates signaling cascades that induce proliferation and differentiation of megakaryocytes leading to increased platelet production.
Worked on ELTROMBOPAG at Dr. Reddy's Laboratories? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Sequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP
Study on the Short-term Efficacy and Safety of Recombinant Human Thrombopoietin Combined With Immunosuppressant Sequential Eltrombopag Ethanolamine Dry Suspension in the Treatment of SAA/TD-NSAA
Bioequivalence Study of Revolade® Eltrombopag 50 mg
Ripertamab Plus Eltrombopag vs. Eltrombopag in ITP Patients Post-Steroid Failure
Eltrombopag for Peripheral Blood Stem Cell Harvest